Breast Cancer Molecular Subtypes Predict Response to Anthracycline/Taxane-Based Chemotherapy

被引：0
|
作者：
Parker, J. S.
Prat, A.
Cheang, M. C. U.
Lenburg, M. E.
Paik, S.
Perou, C. M.
机构：
[1] Univ N Carolina, Chapel Hill, NC USA
[2] Boston Univ, Sch Med, Boston, MA 02118 USA
[3] Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA
来源：
CANCER RESEARCH | 2009年 / 69卷 / 24期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：598S / 598S
页数：1
相关论文
共 50 条
  • [1] Pathologic Response Rates Following Neoadjuvant Anthracycline and Taxane-based Chemotherapy for Early Breast Cancer (EBC)
    Redana, S.
    Papadimitraki, E.
    Mohammed, K.
    Lote, H.
    Sharp, A.
    Capelan, M.
    [J]. CLINICAL ONCOLOGY, 2017, 29 (06) : E103 - E103
  • [2] Tumor-infiltrating lymphocytes to predict survival to anthracycline/taxane-based neoadjuvant chemotherapy in breast cancer.
    Ou, Qiyun
    Yu, Yunfang
    Xiao, Xiaoyun
    Luo, Baoming
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [3] Chemotherapy Response Assay Test and Prognosis for Breast Cancer Patients Who Have Undergone Anthracycline-and Taxane-Based Chemotherapy
    Lee, Anbok
    Lim, Woosung
    Moon, Byung-In
    Paik, Nam-Sun
    Koh, Suck-Hwan
    Song, Jeong-Yoon
    [J]. JOURNAL OF BREAST CANCER, 2011, 14 (04) : 283 - 288
  • [4] Molecular signatures that predict response to anthracycline-taxane based neoadjuvant chemotherapy
    Blackwell, KL
    Dressman, H
    Olson, J
    Rosen, E
    Marcom, PK
    Liotcheva, V
    Jones, E
    Vujaskovic, Z
    Huper, G
    Marks, J
    Dewhirst, M
    West, M
    Nevins, J
    [J]. BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S22 - S22
  • [5] Influence of anthracycline- and/or taxane-based chemotherapy on bone metabolism of patients with primary breast cancer
    Kurbacher, C. M.
    Rauschenbach, N.
    Kurbacher, A. T.
    Herz, S.
    Monreal, K.
    Bartling, C.
    Kurbacher, J. A.
    Quade, A.
    [J]. ANNALS OF ONCOLOGY, 2015, 26
  • [6] A 3-gene biomarker signature to predict response to taxane-based neoadjuvant chemotherapy in breast cancer
    Kallarackal, Jim
    Burger, Florian
    Bianco, Stefano
    Romualdi, Alessandro
    Schad, Martina
    [J]. PLOS ONE, 2020, 15 (03):
  • [7] Body Composition, Adherence to Anthracycline and Taxane-Based Chemotherapy, and Survival After Nonmetastatic Breast Cancer
    Cespedes Feliciano, Elizabeth M.
    Chen, Wendy Y.
    Lee, Valerie
    Albers, Kathleen B.
    Prado, Carla M.
    Alexeeff, Stacey
    Xiao, Jingjie
    Shachar, Shlomit S.
    Caan, Bette J.
    [J]. JAMA ONCOLOGY, 2020, 6 (02) : 264 - 270
  • [8] Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers
    Lee, Hee Jin
    Park, In Ah
    Song, In Hye
    Kim, Sung-Bae
    Jung, Kyung Hae
    Ahn, Jin-Hee
    Ahn, Sei-Hyun
    Kim, Hak Hee
    Gong, Gyungyub
    [J]. PLOS ONE, 2015, 10 (09):
  • [9] Tumor-infiltrating lymphocytes to predict survival to anthracycline/taxane-based adjuvant chemotherapy in triple negative breast cancer.
    Ou, Qiyun
    Yu, Yunfang
    Xiao, Xiaoyun
    Luo, Baoming
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (05)
  • [10] Single Institution trial of anthracycline- and taxane-based chemotherapy for operable breast cancer: The ASTER study
    Mariani, Gabriella
    Galli, Giulia
    Cavalieri, Stefano
    Valagussa, Pinuccia
    Bianchi, Giulia Valeria
    Capri, Giuseppe
    Cresta, Sara
    Ferrari, Laura
    Damian, Silvia
    Duca, Matteo
    de Braud, Filippo
    Moliterni, Angela
    [J]. BREAST JOURNAL, 2019, 25 (02): : 237 - 242
12345